anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Randomization Phase: Participants will receive blinded study drug (lenvatinib/placebo) in 2:1 ratio until documentation of disease progression (confirmed by independent imaging review), development of unacceptable toxicity, or withdrawal of consent. After having completed the primary analysis, subjects treated with lenvatinib who have not experienced disease progression may request to continue open label lenvatinib at the same dose, according to the clinical judgment of the investigator. Participants who discontinue treatment for any reason other than disease progression will be followed in the Randomization Phase until disease progression or start of another anticancer treatment; these participants then enter the Extension Phase for survival follow-up. Extension Phase: Participants in the placebo arm who have disease progression confirmed by IIR could request to enter the OOL Lenvatinib Treatment Period and receive lenvatinib treatment. Participants will receive lenvatinib treatment until disease progression (investigator's assessment), development of intolerable toxicity, or withdrawal of consent. Participants who had disease progression during the Randomization Phase and did not enter the OOL Lenvatinib Treatment Period and all participants who discontinued lenvatinib treatment in the OOL Lenvatinib Treatment Period will enter the follow-up period. Participants will be followed for survival, and all anticancer treatments will be recorded until the time of death.
The current study uses a safe, convenient bedside imaging tool called contrast-enhanced ultrasound (CEUS) to measure the extent of microvascular perfusion impairment in the heart, kidneys and/or brain of COVID-19 pediatric patients and, as exploratory analysis, to assess the significance of imaging findings by correlating to clinical outcomes.

Sulfur hexafluoride lipid-type A microspheres (LumasonTM, Bracco Inc) is an FDA-approved ultrasound contrast agent. Contrast-enhanced ultrasound scan with a duration of approximately 15 minutes will be performed when a COVID-19 diagnosis has been made (or is highly suspected) according to established clinical procedures. One CEUS will be performed per patient, with up to 2 intravenous injections of the contrast agent. The dosing plan will be weight-adjusted, based on a dose of 0.03 mL/kg (with a maximum dose of 2.4 mL per injection). Organ perfusion will be evaluated in the heart, kidneys, and/or brain. Clinical outcomes during hospital stay will be collected for correlation to CEUS-based measures.
Depakote ER is a valproate and is indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgment, aggressiveness, and possible hostility. A mixed episode is characterized by the criteria for a manic episode in conjunction with those for a major depressive episode (depressed mood, loss of interest or pleasure in nearly all activities).

The efficacy of Depakote ER is based in part on studies of Depakote (divalproex sodium delayed release tablets) in this indication, and was confirmed in a 3-week trial with patients meeting DSM-IV TR criteria for bipolar I disorder, manic or mixed type, who were hospitalized for acute mania [see Clinical Studies (14.1)].

The effectiveness of valproate for long-term use in mania, i.e., more than 3 weeks, has not been demonstrated in controlled clinical trials. Therefore, healthcare providers who elect to use Depakote ER for extended periods should continually reevaluate the long-term risk-benefits of the drug for the individual patient.
The present invention discloses chondroitin sulfate which can be used for administration in an intravenous injection approach, and a preparation method of chondroitin sulfate. A preparation prepared from a purified chondroitin sulfate not only can be used for intramuscular injection, but also can be used for intravenous administration in the methods that the preparation is added into the infusion liquid of dextrose or physiological saline or is directly pushed and injected, etc. The use of the preparation is greatly convenient, and the pain of the intramuscular injection for administration for many times is reduced. The chondroitin sulfate with the purpose overcomes the defects of low purity and immunogenicity of the injection liquid of the chondroitin sulfate of the prior art. The chondroitin sulfate is directly injected to enter a blood circulation system. The chondroitin sulfate has the advantages of high blood drug concentration, rapid effect taking, favorable therapeutic effect and low side effects.
A health medicated liquor for preventing and treating insomnia, amnesia, and mental depression. The invention belongs to the technical field of medicinal preparations, and particularly relates to a pure traditional Chinese medicine health wine capable of effectively preventing and treating mental depression, insomnia and dreaminess. The composition of the medicinal liquor is prepared from the following Chinese medicinal raw materials and auxiliary materials in parts by weight: 1. 5-15 g of spina date seed; 2. 8-10 g of eucommia; 3. 6-15 g of platycladi seed; 4. 10-15 g of polygala; 5. 8-15 g of cortex albiziae; 6. 15-30 g of tuber fleeceflower stem; 7. 10-15 g of safflower; 8. 10-15 g of medlar; 9. 10-15 g of liquorice; 10. 25 g of brown sugar; 11. 25 g of white sugar; 12. 500 g of white spirit; 13. 1 g of edible essence. The production process of the product of the invention comprises the following steps: 1) cleaning the Chinese medicinal slices with clear water, and spin-drying with a spin dryer. 2) And putting the dried medicinal materials into a high-temperature disinfection cabinet for sterilization and disinfection. 3) Adding sterilized Chinese medicinal materials into a pottery jar, adding Chinese liquor, brown sugar and white sugar, sealing, fermenting, stirring for 3 times every day, filtering after 7 days, taking out residues, and adding edible essence to obtain the final product.
Unscheduled (breakthrough) bleeding and spotting sometimes occur in patients on COCs, especially during the first 3 months of use. If bleeding persists, check for causes such as pregnancy or malignancy. If pathology and pregnancy are excluded, bleeding irregularities may resolve over time or with a change to a different COC. 

When prescribing Seasonique, the convenience of fewer planned menses (4 per year instead of 13 per year) should be weighed against the inconvenience of increased unscheduled bleeding and/or spotting. The primary clinical trial (PSE-301) that evaluated the efficacy of Seasonique also assessed unscheduled bleeding. The participants in the 12-month clinical trial (N=1,006) completed the equivalent of 8,681 28-day cycles of exposure and were composed primarily of women who had used oral contraceptives previously (89%) as opposed to new users (11%). A total of 82 (8.2%) of the women discontinued Seasonique, at least in part, due to bleeding or spotting.

Scheduled (withdrawal) bleeding and/or spotting remained fairly constant over time, with an average of 3 days of bleeding and/or spotting per each 91-day cycle. Unscheduled bleeding and unscheduled spotting decreased over successive 91-day cycles. Table 1 below presents the number of days with unscheduled bleeding in treatment cycles 1 and 4. Table 2 presents the number of days with unscheduled spotting in treatment cycles 1 and 4.

Figure 1 shows the percentage of Seasonique subjects participating in trial PSE-301 with ≥ 7 days or ≥ 20 days of unscheduled bleeding and/or spotting, or only unscheduled bleeding, during each 91-day treatment cycle.

Figure 1. Percent of Women Taking Seasonique who Reported Unscheduled Bleeding and/or Spotting or only Unscheduled Bleeding

Amenorrhea sometimes occurs in women who are using COCs. Pregnancy should be ruled out in the event of amenorrhea. Some women may encounter amenorrhea or oligomenorrhea after stopping COCs, especially when such a condition was pre-existent.
AT is an α2-globulin that is produced primarily in the liver. It binds thrombin, as well as other serine proteases, factors IX, X, XI, and XII, kallikrein, and plasmin irreversibly, which neutralizes their activity. However, only inhibition of thrombin and factor Xa by AT has physiologic and clinical significance.1 AT deficiency may occur as a congenital or acquired deficiency. Acquired deficiencies are secondary to increased AT consumption, loss of AT from the intravascular compartment (renal failure, nephrotic syndrome) or liver disease (cirrhosis). A normal AT level is 80% to 120% with activity below 50% considered clinically important based on the risk of venous thrombosis in patients with congenital deficiency of AT.2 However, the risk of thrombosis is higher in congenital forms than acquired forms of AT deficiency.3, 4 Unfortunately, the only abnormal coagulation test associated with this condition is the assay for AT activity, which is diagnostic but not readily available.

Acquired deficiencies of AT are commonly encountered in cardiac surgical patients. Anticoagulation with heparin for CPB depends on AT to inhibit clotting as heparin alone has no effect on coagulation. Heparin catalyzes AT inhibition of thrombin over a 1000 fold by binding to a lysine residue on AT and altering its conformation. Thrombin actually attacks AT, disabling it, but in the process attaches AT to thrombin, forming a complex that can be detected and used to assess thrombin formation but has no activity. Thirty percent of AT is consumed during this process so AT levels are reduced temporarily. If AT levels are not restored, then a condition may arise called heparin resistance. There are other less frequent causes of heparin resistance besides AT deficiency such as platelets, fibrin, vascular surfaces and plasma proteins.5 There is no universally accepted definition of heparin resistance. It is broadly defined as the failure of a specific heparin dose (300 - 400 u/kg) to prolong an ACT beyond 400 - 480 seconds in preparation for initiation of CPB. Because the definition of heparin resistance may differ according to both heparin dose and target ACT, the incidence of heparin resistance in the literature is very variable. A recent randomized prospective study analyzing 2270 cardiac cases, identified 3.7% of the patients to be heparin resistant but the incidence has been reported as high as 18% - 30% The incidence of heparin resistance is likely to further increase as the use of heparin infusions prior to cardiac surgery becomes more prevalent.
The present invention discloses a manufacture method for capsule used for removing stagnation, alleviating pain, strengthening tendon and bone. The method is realized in a way that: baking centipede, scorpio, dung beetle, black-tail snake, eupolyphage sinensis, licorice, honeycomb, tiger bone, hairy birthwort, lycopodium clavatum, schizophragma intetrifolia, herba pyrolae, angelica and geranium are made into dry medicinal powder and then mixed proportionally with magnesium stearate. Ethanol is taken as the humectant to make the mixture into waterish particles, which are dried and capsulated. Medicine made by adopting the method of the present invention is simple in composition, definitude, advanced in technology, easy in quality control, high in technology content, convenient in taking, good in mouthfeel, difficult in moisture absorption and good in stability; the capsule has the advantages of high bioavailability, equivalent curative effect with other medicament forms. The preparation is reasonable in design, convenient in taking, and convenient in carrying. The preparation has unique curative effect in removing stagnation, alleviating pain, and strengthening tendon and bone.
PURPOSE:The titled preparation that is made by confining urokinase in spaces in fine lipid particles, thus removing bad influences caused by parenteral administration and making it possible to keep prolonged activity in blood. CONSTITUTION:A solution of a lipid, e.g., phospholipid such as lecithin or phosphatidylcholine, in a solvent that causes no denaturation of the lipid such as ethanol is treated to remove the solvent. Then, the lipid is made into films. At this time, cholesterol or phosphatidic acid may be added as a stabilizer. Another solution of urokinase in a solvent that causes no denaturation of the lipid such as a phosphoric acid buffer solution of 6-8pH is added to the film and they are vigorously stirred. Preferably, they are treated with ultrasonic waves to disperse the film uniformly, resulting in the inclusion of urokinase in spaces of the lipid. The addition of a high- molecular stabilizer such as albumin gives the preparation with highly increased stability.
Cancer cells are blocked from entering differentiation pathways because of abnormal methylation enzymes, which are responsible for keeping cancer cells in cycling state. Effective differentiation inducers are those capable of acting directly or indirectly to convert abnormal methylation enzymes into normal enzymes, thereby enabling cancer cells to undergo terminal differentiation. Differentiation employing inducer alone often can not reach completion because of the damage created by the inducer. Such damage can be prevented if differentiation is induced in the presence of helper inducers, which are basically inhibitors of the component enzymes of differentiation. Thus, differentiation induced in the presence of helper inducers is more likely to reach completion. Therefore, helper inducers are essential components of differentiation therapy, not just merely to potentiate the activity of differentiation inducers. The present inventors discover phenylacetamides, alkyl phenylacetate, 2,4-dichlorophenylacetate, indole acetate, ethidium bromide, hycanthone, and riboflavin are potent helper inducers.
PROBLEM TO BE SOLVED: To obtain the subject new inhibitor, comprising an essence of a plant belonging to the genus Ligustrum of the family Oleaceae, useful for treating lipid dysbolism and having high safety. SOLUTION: This inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activities comprises an essence of a plant belonging to the genus Ligustrum of the family Oleaceae. Ligustrum purpurascens, Ligustrum pedunculare, etc., are preferably used as the plant. An essence obtained by extracting a leaf part thereof with warm water, then adsorbing the resultant extract on a specific adsorbent, eluting the adsorbed extract with ethanol and further concentrating the eluate under a reduced pressure is preferred as the essence thereof. The inhibitor is preferably perorally administered; however, in the case of peroral administration, the daily dose thereof for an adult is preferably 5-500mg administered in several divided portions. When the essence is used as a parenteral injection, the dose thereof is preferably 1-100mg.  When the inhibitor is blended in a food composition, the content thereof is preferably 0.1-1wt.%.
The invention discloses red jujube health-care liquor and a production process thereof. Liquor, red jujubes, grape pips, roses and the like are selected as raw materials, and the red jujube health-care liquor is obtained by heat soaking, low-temperature soaking and repeated treatment of the raw materials. The red jujube health-care liquor is integrated with a plurality of functional raw materials, contains a plurality of effective ingredients such as general flavone, rhodioloside, crude polysaccharides and total saponins, and has multiple health-care efficacies of alleviating fatigue, enhancing immunity, promoting metabolism, promoting blood circulation, removing blood stasis, helping people maintain beauty and keep young, and removing chloasma. The red jujube health-care liquor is crystal and transparent, has unique flavor and health-care efficacy, and is suitable for long-term drinking. The product is clear, glossy, fragrant and pure and mild in taste, sweet and chill, refreshing and soft, and representative, and has a balanced body, long-lasting flavor and unique style. The production method is simple, raw materials used in preparing the red jujube health-care liquor are easy to obtain, and the red jujube health-care liquor is easy for popularization.
FIELD: medicine, gastroenterology. SUBSTANCE: method involves carrying out the basic therapy with anti- -secretory and antibacterial preparations. Method involves additional and simultaneous prescription of intake of nettle dried leaves infusion in the ratio raw : water = 5:100 at the dose two table-spoons, three times per a day, 15-20 min before eating and up to appearance of scarring symptoms. Then intake if nettle dried leaves infusion in combination with supporting dose of histamine H 2 -antagonists is continued and one month before of expected exacerbation nettle dries leaves infusion is prescribed only for 2-3 months in the same doses. EFFECT: enhanced effectiveness of treatment, decreased complication cases, decreased treatment period, increased remission time. 1 ex
BACKGROUND: Arteriovenous fistulae (AVF) complicated by aneurysms are repaired through several mechanisms. Little is known about risk factors for aneurysm recurrence or the efficacy of subsequent repair of recurring aneurysms.
METHODS: About 291 patients underwent AVF aneurysm repair between 2009 and 2019 at a large urban medical center. Patients who underwent staged repair, had a primary graft with pseudoaneurysm, were status-post kidney transplant, or using other dialysis access at the time of repair were excluded. One hundred sixty-two patients were included in the study, of which 52 developed a secondary aneurysm. Chi-square and t-test analyses were used to compare demographics. Multivariate logistic regression was used to examine independent risk factors for aneurysm recurrence. Of the 52 patients with recurrent aneurysms, 41 were repaired again. Patency was examined for each group 1 year postoperatively.
RESULTS: Patients without secondary aneurysms were more likely to have a Charlson Comorbidity Index score ⩾5 (p = 0.045). Males were 2.8 times more likely to develop a secondary aneurysm compared to females (p = 0.023). Patients who underwent elective compared to emergent or urgent surgery for primary aneurysms were significantly less likely to recur (OR = 0.222; p = 0.016). Primary aneurysms repaired by end-to-end anastomosis, compared to aneurysmorrhaphy or graft, were significantly less likely to recur (OR = 0.239; p = 0.041). Among patients with secondary aneurysms, those repaired via end-to-end anastomosis had a significantly higher primary patency rate 1 year postoperatively (p = 0.024). Secondary aneurysm repairs exhibited 1-year primary and secondary patency rates of 51.2% and 82.9%, respectively.
CONCLUSIONS: End-to-end anastomosis reduces risk of recurrence and demonstrates superior patency rates when repairing recurrent aneurysms. It remains unclear why some patients are prone to aneurysm recurrence, however continued attempts to repair existing vascular access are proven to be successful.
Recent studies at the AIDS vaccine units have shown the safety of two candidate HIV vaccines, HIVAC-1e and gp160. Specific questions to be addressed in this part of the study include: Does combination vaccination result in a synergistic (added) response not predicted by just the addition of a second vaccination, and does this synergism depend on the unique priming effect of a vaccinia recombinant, or will any combination do?

Volunteers will be randomized to one of four groups. Group A (20 volunteers) will receive gp160 (VaxSyn) followed two months later by a repeat dose. Group B (20 volunteers) will receive VaxSyn followed two months later by HIVAC-1e. Group C (20 volunteers) will receive HIVAC-1e followed two months later by VaxSyn. Group D (10 volunteers) will receive HIVAC-1e followed two months later by HIVAC-1e. For volunteers in Groups A, B, and C who do not react to the initial vaccination, a second attempt to obtain a reaction may be made 7 or more days following the initial inoculation. Per addendum, two additional booster inoculations are given: one at 6 months or later post initial inoculation (Groups A, C, and D receive VaxSyn and Group B receives HIVAC-1e) and another at 12 months or later (all Groups receive VaxSyn).
PURPOSE: This study evaluates three different language sample elicitation strategies to determine a valid elicitation strategy for early language learners who speak using augmentative and alternative communication (AAC).
METHOD: Ten children who speak using AAC participated in this study. Language samples were elicited from each participant using three strategies: the Communication and Symbolic Behavior Scales (CSBS), a generic play-based elicitation strategy, and automatic data logging. Samples were transcribed and coded. Additionally, each participant's school speech-language pathologist completed a Communication Matrix. Data from coded language samples were correlated with Communication Matrix results to determine the elicitation strategy that yielded the most valid language sample in comparison to Communication Matrix results.
RESULTS: Both the CSBS and the play-based strategy yielded clinically relevant information. Because the log lacked communicative context, resulting data from the log was limited. An analysis of variance revealed significant differences in the amount of information elicited from each elicitation strategy. The CSBS repeatedly elicited the most data, followed by the play-based strategy and then the log. Generic play-based strategy results yielded the most correlations with Communication Matrix data.
CONCLUSIONS: This preliminary data suggest that the play-based elicitation strategy elicited the most valid language sample when compared to the Communication Matrix from early language learners who speak using AAC. Additionally, results suggest that the CSBS may be an effective tool to measure the limits of this population's expressive language abilities.
This is a multi-center triple blinded randomized clinical trial in which we'll compare two techniques for the treatment of simple low transsphincteric perianal fistulas. 40 patients will undergo a fistulotomy with marsupialization and 40 patients will undergo a fistulotomy with open wound. There will be an inclussion visit in which personal information will be recorded and the consent will be signed. Randomization will be done after inclusion, following a balanced blocks model. Information of the surgery technic won't be available for the investigator. The patients will have a journal in which they'll write their postoperative symptoms. Follow up will be done at weeks 2, 4 and 6 by the main investigator of each center. Data will be based in clinical examination, patient's diary and medical records. Statistical analysis of the primary outcome will be based in a superiority analysis using the Mantel-Cox test, or in case needed, a multivariate Cox regression analysis. The secondary outcomes will be analyzed by comparing times, percentages, mean or median with parametric or non parametric tests as it corresponds.